Výsledky vyhľadávania - "PLATINUM-DOUBLET CHEMOTHERAPY"

Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

Autori: Armando Santoro Garrido Pilar Daniel S.W. Tan a ďalší

Zdroj: BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)

Predmety: Canakinumab, NSCLC, PD-L1, Platinum-doublet chemotherapy, Spartalizumab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Popis súboru: electronic resource

Relation: https://doaj.org/toc/1471-2407

Prístupová URL adresa: https://doaj.org/article/49d4a4474e494f5081ff231d7fc7b4f8

Excessive esophageal toxicity in patients with locally advanced non-small cell lung cancer treated with concurrent hypofractionated chemoradiotherapy and 3-weekly platinum doublet chemotherapy

Autori: Noëlle van der Voort van Zyp Masoma Hashimzadah Erik Kouwenhoven a ďalší

Zdroj: Clin Transl Radiat Oncol
Clinical and Translational Radiation Oncology, Vol 36, Iss, Pp 70-76 (2022)

Predmety: Medical physics. Medical radiology. Nuclear medicine, 03 medical and health sciences, 0302 clinical medicine, R895-920, Concurrent chemoradiation, Hypofractionation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Non-small cell lung cancer (NSCLC), Original Research Article, Esophageal toxicity, Platinum doublet chemotherapy, RC254-282, 3. Good health

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/35847053
https://doaj.org/article/67b980b5c1374de88616d34468bdd3fd

Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study: a registry-based descriptive study

Autori: David Lang Wolfgang Haslinger Kaveh Akbari a ďalší

Prispievatelia: David Lang Wolfgang Haslinger Kaveh Akbari a ďalší

Zdroj: Lung Cancer (Auckl)
Lung Cancer: Targets and Therapy, Vol Volume 11, Pp 113-121 (2020)

Predmety: nivolumab, carcinoembryonic antigen, Targets and Therapy [Lung Cancer], Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, 03 medical and health sciences, platinum doublet chemotherapy, 0302 clinical medicine, RECIST, cyfra 21-1, CYFRA 21-1, pembrolizumab, recist, RC254-282, Original Research

Popis súboru: text/html

Prístupová URL adresa: https://www.dovepress.com/getfile.php?fileID=64983
https://pubmed.ncbi.nlm.nih.gov/33376433
https://doaj.org/article/de62df45ecee46c7bf7642e198ce9c9e
https://www.dovepress.com/serum-tumor-marker-dynamics-as-predictive-biomarkers-in-nsclc-chemo-im-peer-reviewed-article-LCTT
https://www.scilit.net/article/7cddf6848bac8c8841477b14229327cb?action=show-references
https://europepmc.org/article/MED/33376433
https://www.dovepress.com/serum-tumor-marker-dynamics-as-predictive-biomarkers-in-nsclc-chemo-im-peer-reviewed-fulltext-article-LCTT
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755331
https://epub.jku.at/obvulioa/content/titleinfo/5697358
https://pubmed.ncbi.nlm.nih.gov/33376433/
https://permalink.obvsg.at/ULI/AC16119783
https://doi.org/10.2147/lctt.s286228
https://epub.jku.at/id/5697358

Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges

Autori: Mountzios, Giannis Remon, Jordi Hendriks, Lizza E. L. a ďalší

Zdroj: Mountzios, G, Remon, J, Hendriks, L E L, Garcia-Campelo, R, Rolfo, C, Van Schil, P, Forde, P M, Besse, B, Subbiah, V, Reck, M, Soria, J-C & Peters, S 2023, 'Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges', Nature Reviews Clinical Oncology, vol. 20, no. 10, pp. 664-677. https://doi.org/10.1038/s41571-023-00794-7

Predmety: PLATINUM-DOUBLET CHEMOTHERAPY, NEOADJUVANT CHEMOTHERAPY, PHASE-III, ADJUVANT CHEMOTHERAPY, OPEN-LABEL, PATHOLOGICAL RESPONSE, DOCETAXEL-CISPLATIN, SUPPORTIVE CARE, POOLED ANALYSIS, SINGLE-CENTER

Popis súboru: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/37488229; info:eu-repo/semantics/altIdentifier/wos/001034522900002; info:eu-repo/semantics/altIdentifier/pissn/1759-4774; info:eu-repo/semantics/altIdentifier/eissn/1759-4782

Dostupnosť: https://cris.maastrichtuniversity.nl/en/publications/6645882b-514d-48a7-841a-0c82e0f58a4f
https://doi.org/10.1038/s41571-023-00794-7
https://cris.maastrichtuniversity.nl/ws/files/225313593/Hendriks-2024-Immune-checkpoint-inhibition-for-resectable.pdf
https://www.scopus.com/pages/publications/85165614144

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Autori: Reck, Martin Schenker, Michael Lee, Ki Hyeong a ďalší

Prispievatelia: Reck, Martin Schenker, Michael Lee, Ki Hyeong a ďalší

Zdroj: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Universidad Autónoma de Madrid

Predmety: Quality of life, Adult, Male, Lung Neoplasms, Medicina, Health Status, Nonesmall-cell lung cancer, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Lung neoplasms, Carcinoma, Non-Small-Cell Lung, Antineoplastic agents, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Humans, Patient Reported Outcome Measures, Nivoluma, Nonâ€'small-cell lung cancer, Aged, Non–small-cell lung cancer, Carcinoma, Middle Aged, Ipilimumab, 3. Good health, Nivolumab, Quality of Life, Platinum-doublet chemotherapy, Female, Surveys and questionnaires

Popis súboru: application/pdf

Prístupová URL adresa: http://www.ejcancer.com/article/S0959804919303119/pdf
https://pubmed.ncbi.nlm.nih.gov/31195357
https://hdl.handle.net/20.500.12530/83750
http://hdl.handle.net/10486/691172
https://www.ncbi.nlm.nih.gov/pubmed/31195357
https://europepmc.org/abstract/MED/31195357
https://www.sciencedirect.com/science/article/pii/S0959804919303119
https://ro.ecu.edu.au/cgi/viewcontent.cgi?article=7310&context=ecuworkspost2013
https://repositorio.uam.es/bitstream/10486/691172/1/nivolumab_reck_EJC_2019.pdf
https://www.sciencedirect.com/science/article/abs/pii/S0959804919303119
https://hdl.handle.net/10486/691172
https://doi.org/10.1016/j.ejca.2019.05.008

Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer

Autori: Levy, B.P. Signorovitch, J.E. Yang, H. a ďalší

Zdroj: Current Oncology
Volume 26
Issue 3
Pages 4485-308

Predmety: Male, Lung Neoplasms, Paclitaxel, comparative analyses, Antineoplastic Agents, Deoxycytidine, Carboplatin, 03 medical and health sciences, squamous cell lung cancer, 0302 clinical medicine, Albumins, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Humans, chart reviews, Aged, Middle Aged, Survival Analysis, Gemcitabine, 3. Good health, platinum doublet chemotherapy, Treatment Outcome, Carcinoma, Squamous Cell, Female, immunotherapy, Immunotherapy, Non-small-cell lung cancer

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/31285672
https://current-oncology.com/index.php/oncology/article/view/4485
https://pubmed.ncbi.nlm.nih.gov/31285672/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588060
https://www.ncbi.nlm.nih.gov/pubmed/31285672
https://jhu.pure.elsevier.com/en/publications/effectiveness-of-first-line-treatments-in-metastatic-squamous-non
https://www.mdpi.com/1718-7729/26/3/4485

Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study

Autori: Lang D Haslinger W Akbari K a ďalší

Zdroj: Lung Cancer: Targets and Therapy, Vol 11, Pp 113-121 (2020)

Predmety: carcinoembryonic antigen, platinum doublet chemotherapy, pembrolizumab, cyfra 21-1, recist, nivolumab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Popis súboru: electronic resource

Relation: https://www.dovepress.com/serum-tumor-marker-dynamics-as-predictive-biomarkers-in-nsclc-chemo-im-peer-reviewed-article-LCTT; https://doaj.org/toc/1179-2728

Prístupová URL adresa: https://doaj.org/article/de62df45ecee46c7bf7642e198ce9c9e

EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%

Autori: Sezer, A. Kilickap, S. Gumus, M. a ďalší

Prispievatelia: Sezer, A. Kilickap, S. Gumus, M. a ďalší

Predmety: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%-, ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31 [Sezer A., Kilickap S., Gumus M., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., TÜRK H. M. , Cicin I., Bentsion D., Gladkov O., et al., -EMPOWER-Lung 1]

Popis súboru: application/pdf

Prístupová URL adresa: http://hdl.handle.net/20.500.12645/27357

A Comparative Analysis between Real-World Data and Clinical Trials to Evaluate Differences in Outcomes for SCLC Patients

Autori: Marzano, Luca Dan, A. Tendler, S. a ďalší

Zdroj: Journal of Thoracic Oncology. 18(11):S697-S697

Predmety: small cell lung cancer, real-world evidence, platinum doublet chemotherapy

Popis súboru: print

Prístupová URL adresa: https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-342734

Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer

Autori: Akira Nakao Hiroyuki Inoue Nobumitsu Ikeuchi a ďalší

Zdroj: J Clin Med
Journal of Clinical Medicine; Volume 12; Issue 1; Pages: 137

Predmety: 03 medical and health sciences, 0302 clinical medicine, thyroid transcription factor-1 (TTF-1), pemetrexed, platinum-doublet chemotherapy, biomarker, non-small-cell lung cancer, Article, 3. Good health

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36614938

A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients.

Autori: Porte M Vaudron A Crequit P a ďalší

Zdroj: Clinical lung cancer [Clin Lung Cancer] 2024 Mar; Vol. 25 (2), pp. e101-e111.e2. Date of Electronic Publication: 2023 Nov 23.

Spôsob vydávania: Multicenter Study; Journal Article

Informácie o časopise: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE

Výrazy zo slovníka MeSH: Lung Neoplasms*/drug therapy , Small Cell Lung Carcinoma*/drug therapy , Brain Neoplasms*, Humans ; Brain ; Immunotherapy

Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227

Autori: Hellmann, Matthew D. Ciuleanu, Tudor Eliade Pluzanski, Adam a ďalší

Zdroj: AACR Annual Meeting 2018

Témy: Ipilimumab, NSCLC, Nivolumab, Platinum-doublet chemotherapy, Contribution to conference

URL: https://eprints.qut.edu.au/133393/1/133393.pdf
https://eprints.qut.edu.au/133393/1/133393.pdf
doi:10.1158/1538-7445.AM2018-CT077
Hellmann, Matthew D., Ciuleanu, Tudor Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory, Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S., Brahmer, Julie, Reck, Martin, O'Byrne, Kenneth J., Geese, William J., Green, George, Chang, Han, Szustakowski, Joseph D., Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, & Paz-Ares, Luis (2018) Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227. In AACR Annual Meeting 2018, 2018-04-14 - 2018-04-18.

Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting.

Autori: Nakayama I Takahari D Wakatsuki T a ďalší

Zdroj: ESMO open [ESMO Open] 2020 Apr; Vol. 5 (2).

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

Výrazy zo slovníka MeSH: Adenocarcinoma/*drug therapy , Esophageal Neoplasms/*drug therapy , Stomach Neoplasms/*drug therapy, Adolescent ; Adult ; Aged ; Cohort Studies ; Humans ; Middle Aged ; Neoplasm Metastasis ; Retrospective Studies ; Young Adult

SCR Disease Name: Adenocarcinoma Of Esophagus

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.

Autori: Yoshioka H Shimokawa M Seto T a ďalší

Zdroj: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2019 Dec 01; Vol. 30 (12), pp. 1978-1984.

Spôsob vydávania: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Informácie o časopise: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

Výrazy zo slovníka MeSH: Carcinoma, Non-Small-Cell Lung/*drug therapy , Cisplatin/*administration & dosage , Docetaxel/*administration & dosage , Gefitinib/*administration & dosage , Neoplasm Recurrence, Local/*drug therapy, Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Non-Small-Cell Lung/epidemiology ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Cisplatin/adverse effects ; Disease-Free Survival ; Docetaxel/adverse effects ; ErbB Receptors/genetics ; Female ; Gefitinib/adverse effects ; Humans ; Japan/epidemiology ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Mutation ; Neoplasm Recurrence, Local/epidemiology ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Proportional Hazards Models ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Treatment Outcome

Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.

Autori: Yoshida T Kuroda H Oya Y a ďalší

Zdroj: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2017 Jul; Vol. 109, pp. 89-91. Date of Electronic Publication: 2017 May 03.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE

Výrazy zo slovníka MeSH: Carcinoma, Non-Small-Cell Lung/*drug therapy , Lung Neoplasms/*drug therapy , Platinum Compounds/*therapeutic use, Adult ; Aged ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Drug Resistance, Neoplasm ; Female ; Genes, erbB-1/genetics ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Mutation/genetics ; Neoplasm Staging ; Protein Kinase Inhibitors/therapeutic use ; Retrospective Studies ; Survival Analysis ; Treatment Failure ; Treatment Outcome

A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.

Autori: Harris JP Patel MI Loo BW a ďalší

Zdroj: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2017 Jun; Vol. 108, pp. 173-182. Date of Electronic Publication: 2017 Mar 29.

Spôsob vydávania: Journal Article; Research Support, Non-U.S. Gov't

Informácie o časopise: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE

Výrazy zo slovníka MeSH: Carcinoma, Non-Small-Cell Lung/*pathology , Carcinoma, Non-Small-Cell Lung/*therapy , Lung Neoplasms/*pathology , Lung Neoplasms/*therapy, Carcinoma, Non-Small-Cell Lung/epidemiology ; Carcinoma, Non-Small-Cell Lung/mortality ; Chemoradiotherapy/adverse effects ; Chemoradiotherapy/methods ; Female ; Humans ; Lung Neoplasms/epidemiology ; Lung Neoplasms/mortality ; Male ; Neoplasm Staging ; Population Surveillance ; SEER Program ; Treatment Outcome

Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer.

Autori: Stinchcombe TE Borghaei H Barker SS a ďalší

Zdroj: Clinical lung cancer [Clin Lung Cancer] 2016 Jan; Vol. 17 (1), pp. 1-9. Date of Electronic Publication: 2015 Jul 30.

Spôsob vydávania: Journal Article; Research Support, Non-U.S. Gov't; Review

Informácie o časopise: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE

Výrazy zo slovníka MeSH: Molecular Targeted Therapy*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*drug therapy , ErbB Receptors/*antagonists & inhibitors , Lung Neoplasms/*drug therapy, Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Humans ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Pemetrexed/administration & dosage ; Platinum/administration & dosage

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: Patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Autori: Reck, Martin Schenker, Michael Lee, Ki Hyeong a ďalší

Zdroj: European Journal of Cancer; 137

Témy: Antineoplastic agents, Carcinoma, Ipilimumab, Lung neoplasms, Nivolumab, Non–small-cell lung cancer, Platinum-doublet chemotherapy, Quality of life, Surveys and questionnaires, Medicine and Health Sciences, Journal Article

URL: https://ro.ecu.edu.au/ecuworkspost2013/6305